- Conditions
- Lung Cancer
- Interventions
- HPPH, endoscopic procedure
- Drug · Procedure
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- Buffalo, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1297–1320
of 1,771
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
- Interventions
- bortezomib, gemcitabine hydrochloride
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Tumor or Lymphoma
- Interventions
- JNJ-42756493: Part 1, JNJ-42756493: Part 2, JNJ-42756493: Part 3, JNJ-42756493: Part 4
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 20 more
- Conditions
- Solid Tumor, Renal Cell Cancer Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Prostate Cancer
- Interventions
- EU101
- Drug
- Lead sponsor
- Eutilex
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Dallas, Texas
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma, Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple-negative Breast Cancer
- Interventions
- JANX008
- Drug
- Lead sponsor
- Janux Therapeutics
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 18
- States / cities
- Duarte, California • Sacramento, California • San Diego, California + 15 more
- Conditions
- High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer, Cervical Cancer
- Interventions
- Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin, Itraconazole
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 952 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more
- Conditions
- Locally Advanced Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
- Interventions
- Carboplatin, Durvalumab, Paclitaxel, Papaverine, Radiation Therapy, Pemetrexed, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Computed Tomography, Magnetic Resonance Imaging of the Brain with and without Contrast, Biospecimen Collection
- Drug · Biological · Radiation + 1 more
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 2
- States / cities
- Duarte, California • Columbus, Ohio
- Conditions
- Non-Small-Cell Lung Carcinoma, Prostate Cancer, Bladder Cancer, Urothelial Carcinoma
- Interventions
- vorinostat (suberoylanilide hydroxamic acid), docetaxel
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer, Bladder Cancer, Breast Cancer, Breast Neoplasm, Carcinoma, Ductal, Carcinoma, Hepatocellular, Cancer, Lung Cancer, Non-Small-Cell, Carcinoma, Ovarian Epithelial, Carcinoma, Small Cell, Carcinoma, Squamous, Carcinoma, Transitional Cell, Colorectal Cancer, Esophagogastric Junction Neoplasms, Inflammatory Breast Cancer, Stomach Neoplasms, Malignant Neoplasms, Ovarian Neoplasms, Pancreatic Cancer, HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, Prostate Cancer, Head and Neck Cancer, Endometrial Cancer, Lung Cancer, Small Cell
- Interventions
- CT-0508, Pembrolizumab
- Biological
- Lead sponsor
- Carisma Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 7
- States / cities
- Duarte, California • Chapel Hill, North Carolina • Portland, Oregon + 4 more
- Conditions
- ALK+ Advanced NSCLC
- Interventions
- Brigatinib, Alectinib
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 4
- States / cities
- Whittier, California • Athens, Georgia • Albany, New York + 1 more
- Conditions
- Non-Small Cell Lung Cancer, Prostate Cancer, Pancreatic Cancer
- Interventions
- TH-302
- Drug
- Lead sponsor
- Threshold Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 11
- States / cities
- Scottsdale, Arizona • Indianapolis, Indiana • Shreveport, Louisiana + 7 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- MEDI4736, PLACEBO
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 713 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 60
- States / cities
- Chandler, Arizona • Goodyear, Arizona • Jonesboro, Arkansas + 53 more
- Conditions
- Advanced Solid Tumor Cancer
- Interventions
- ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Death-1 (PD-1) Inhibitor
- Drug
- Lead sponsor
- Calico Life Sciences LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 15
- States / cities
- Tucson, Arizona • New Haven, Connecticut • Baltimore, Maryland + 11 more
- Conditions
- Advanced Non-small Cell Lung Cancer, HER2 Mutation
- Interventions
- Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 444 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 25
- States / cities
- Newport Beach, California • San Diego, California • San Francisco, California + 20 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- PET-Adaptive RT, Erlotinib, Crizotinib
- Radiation · Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2015
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- a novel mobile phone-based intervention for automated electronic PRO collection
- Other
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Nonsmall Cell Lung Cancer, Nonsmall Cell Lung Cancer, Stage II, Nonsmall Cell Lung Cancer Stage III, Unresectable Non-Small Cell Lung Carcinoma
- Interventions
- Genomically Guided Radiation Therapy (RT)
- Radiation
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms, Squamous Cell Cancer of Head and Neck, Small Cell Lung Cancer, Gastroesophageal Cancer, Melanoma, Cervical Cancer, Advanced Solid Tumours
- Interventions
- AZD8701, Durvalumab
- Drug · Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 101 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 6
- States / cities
- Baltimore, Maryland • St Louis, Missouri • Huntersville, North Carolina + 3 more
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- IPH4502
- Drug
- Lead sponsor
- Innate Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Hackensack, New Jersey • New York, New York + 2 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- LGX818
- Drug
- Lead sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- Paclitaxel (Taxane), Docetaxel (Taxane), Carboplatin, Cetuximab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 755 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 124
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 121 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Rociletinib Mono-Therapy, Erlotinib Mono-Therapy
- Drug
- Lead sponsor
- Clovis Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Burbank, California • Duarte, California + 47 more
- Conditions
- Advanced or Metastatic Non-small Cell Lung Cancer
- Interventions
- Rilvegostomig, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel, Ramucirumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Santa Rosa, California • Jacksonville, Florida + 6 more
- Conditions
- Lung Cancer
- Interventions
- gemcitabine hydrochloride, pemetrexed disodium
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 22
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 19 more